Le Lézard
Classified in: Science and technology
Subject: Business Update

Calendly Delivered 318% ROI Finds New Total Economic Impact Study


Calendly, the only centralized scheduling automation platform built for scaling across the organization, today revealed findings from a newly commissioned Total Economic Impact (TEI) study conducted by Forrester Consulting on behalf of Calendly that found customers achieved a 318% ROI and $687,000 in total net benefits over three years by using its technology. The Forrester study found Calendly greatly improves customer satisfaction and retention rates, hiring cycles, cost savings, team productivity, and other key business metrics tied to performance for external teams within the enterprise.

Today's buying process has become much more complex and intensive. As of 2022, organizations use an average of 130 SaaS applications, up from 80 in 2020. Software providers need to prove why they're the right enterprise technology partner to provide maximum strategic value as buyers become more critical of spend. In a recent announcement, Calendly shared adoption of Calendly for Enterprise grew 61% year over year in July, with 86% of the Fortune 500 and 14 of the top 15 Fortune 500 financial companies using the platform today.

"There's nothing better than receiving, in our opinion, this validation from the enterprise and analyst communities," said Tope Awotona, Founder and CEO of Calendly. "I'm proud that our customers choose Calendly to help them with some of their teams' most crucial challenges when it comes to meetings. Our priority is to help them save costs and deliver meaningful business impact across their meeting lifecycle."

Forrester interviewed four customers ? Atlassian, DocuSign, Semrush, and GardaWorld ? to create a composite organization for the study based on Calendly implementation costs, benefits, risks data, and other factors. The TEI study found the following benefits from implementing Calendly:

Key customer quotes shared in the study include:

To read the full Forrester study on Calendly's scheduling automation platform, click here. Visit our website here to learn about Calendly for the Enterprise.

About Calendly

Calendly helps individuals, teams, and organizations automate the meeting lifecycle by removing the back and forth with scheduling. Calendly's cloud-based platform offers a new layer of the modern digital technology stack by connecting with critical tools to automate scheduling workflows, creates a more delightful customer experience, and provides insightful, measurable data to drive better business outcomes. Today, more than 20 million users across 230 countries use Calendly to simplify meetings, collaborate more effectively and efficiently, and drive business forward. To learn more, visit Calendly.com.


These press releases may also interest you

at 00:00
XSOOH has always been at the forefront of hair care innovation, striving to deliver cutting-edge  products  that enhance the way customers achieve their desired looks. In a world where time is precious, XSOOH  proudly announces the launch of the...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...

3 jui 2024
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...

3 jui 2024
"The Classic Quotes by Xi Jinping," a multilingual TV show produced by China Media Group, aired in Kazakhstan on Tuesday after Chinese...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...



News published on and distributed by: